Aspects of Carbon Monoxide in Form of CO-Releasing Molecules Used in Cancer Treatment: More Light on the Way

Review, Article English OPEN
Kourti, Malamati ; Jiang, Wen G. ; Cai, Jun (2017)
  • Publisher: Hindawi Publishing Corporation
  • Journal: Oxidative Medicine and Cellular Longevity, volume 2,017 (issn: 1942-0900, eissn: 1942-0994)
  • Related identifiers: doi: 10.1155/2017/9326454, pmc: PMC5327762
  • Subject: Cytology | Review Article | QH573-671 | Article Subject | R1

Carbon monoxide (CO) has always been recognised as a toxic gas, due to its higher affinity for haemoglobin than oxygen.\ud However, biological studies have revealed an intriguing role for CO as an endogenous signalling molecule, a gasotransmitter. CO is\ud demonstrated to exertmany cellular activities including anti-inflammatory, antiapoptotic, and antiproliferative activities. In animal\ud studies, CO gas administration can prevent tissues from hypoxia or ischemic-reperfusion injury. As a result, there are a plethora\ud of reports dealing with the biological applications of CO and CO-releasing molecules (CORMs) in inflammatory and vascular\ud diseases. CORMs have already been tested as a therapeutic agent in clinical trials. More recently, an increased interest has been\ud drawn to CO’s potential use as an anticancer agent. In this review, we will aim to give an overview of the research focused on the\ud role of COand CORMs in different types of cancer and expand to the recent development of the next generation CORMs for clinical\ud application in cancer treatment.
  • References (57)
    57 references, page 1 of 6

    [1] C. C. Roma˜o and H. L. A. Vieira, “Metal carbonyl prodrugs: CO delivery and beyond,” in Bioorganometallic Chemistry: Applications in Drug Discovery, Biocatalysis, and Imaging, pp. 165-202, Wiley-VCH, 2015.

    [2] R. Foresti, M. G. Bani-Hani, and R. Motterlini, “Use of carbon monoxide as a therapeutic agent: promises and challenges,” Intensive Care Medicine, vol. 34, no. 4, pp. 649-658, 2008.

    [3] F. Gullotta, A. Di Masi, and P. Ascenzi, “Carbon monoxide: an unusual drug,” IUBMB Life, vol. 64, no. 5, pp. 378-386, 2012.

    [4] F. Zobi, “CO and CO-releasing molecules in medicinal chemistry,” Future Medicinal Chemistry, vol. 5, no. 2, pp. 175-188, 2013.

    [5] R. Motterlini, B. E. Mann, and R. Foresti, “eThrapeutic applications of carbon monoxide-releasing molecules,” Expert Opinion on Investigational Drugs, vol. 14, no. 11, pp. 1305-1318, 2005.

    [6] S. Hayashi, Y. Omata, H. Sakamoto et al., “Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene,” Gene, vol. 336, no. 2, pp. 241-250, 2004.

    [7] R. Motterlini and L. E. Otterbein, “eTh therapeutic potential of carbon monoxide,” Nature Reviews Drug Discovery, vol. 9, no. 9, pp. 728-743, 2010.

    [8] B. Wegiel, D. Gallo, E. Csizmadia et al., “Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth,” Cancer Research, vol. 73, no. 23, pp. 7009-7021, 2013.

    [9] A. R. Marques, L. Kromer, D. J. Gallo et al., “Generation of carbon monoxide releasing molecules (CO-RMs) as drug candidates for the treatment of acute liver injury: targeting of CO-RMs to the liver,” Organometallics, vol. 31, no. 16, pp. 5810- 5822, 2012.

    [10] C. C. Roma˜o, W. A. Bla¨ttler, J. D. Seixas, and G. J. L. Bernardes, “Developing drug molecules for therapy with carbon monoxide,” Chemical Society Reviews, vol. 41, no. 9, pp. 3571-3583, 2012.

  • Related Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark